In Phase C, members will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disease progression or the contributors are unable to tolerate the study drugs. Feasible new techniques for the analysis and treatment of AML. (A) The identification https://abbv-744-therapeutic-pote35680.targetblogs.com/32449757/a-review-of-abbv-744-in-combination-with-immunotherapy